Predicting response to azacitidine in MDS



Micrograph showing MDS
Research published in Cell Reports helps explain why some patients with myelodysplastic syndrome (MDS) do not respond to treatment with azacitidine. The study showed that patients who were resistant to the drug had relatively quiescent hematopoietic progenitor cells (HPCs). A smaller proportion of their HPCs were undergoing active cell-cycle progression when... [Read Article]

Vaccine granted orphan designation for MDS



Micrograph showing MDS
The US Food and Drug Administration (FDA) has granted orphan drug designation to DSP-7888, an investigational cancer peptide vaccine, for the treatment of myelodysplastic syndromes (MDS). DSP-7888 contains peptides to induce Wilms' tumor gene 1 (WT1)-specific cytotoxic T lymphocytes and helper T cells, which attack WT1-expressing cancerous cells found in... [Read Article]

Company discontinues phase 3 trial of vadastuximab talirine in AML



AML cells
On the advice of the Independent Data Monitoring Committee, Seattle Genetics is discontinuing the phase 3 CASCADE clinical trial of vadastuximab talirine as frontline treatment in older patients with acute myeloid leukemia (AML). The company is also suspending patient enrollment and treatment in all its vadastuximab trials, including the ongoing phase 1/2 trial... [Read Article]

Azacitidine alone comparable to AZA combos for most MDS patients



Micrograph showing MDS
A 3-arm phase 2 study of azacitidine alone or in combination with lenalidomide or vorinostat in patients with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) has shown the combination therapies to have similar overall response rates (ORR) to azacitidine monotherapy. Based on these findings, investigators did not choose either... [Read Article]

Study shows similar outcomes with RIC and MAC in MDS



HSCT preparation
Photo by Chad McNeeley
Results of a phase 3 trial revealed similar outcomes in patients who underwent allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat myelodysplastic syndromes (MDS), regardless of the conditioning regimen they received. Rates of engraftment, graft-vs-host disease (GVHD), relapse, and survival were similar between patients who received reduced-intensity... [Read Article]